The Aslib-Emerald Award, currently in its seventh year, recognizes the most outstanding contribution to information management good practice published during 2009 in any of the six Aslib-Emerald journals.
The winning paper for 2010 has been chosen by Aslib as it is an incisive, pragmatic and considered examination of a very important issue of today. The winning paper is:
Prostate Cancer Canada invites applications for a literature review of the research into the role of modifiable risk factors in prostate cancer prevention. The systematic review should examine what is known about prostate cancer prevention (including research into diet, supplements and physical activity), what gaps exist in the research, and the level of evidence which exists for various modifiable risk factors in prostate cancer prevention. The current competition aims to identify and review existing research in order to provide PCC with a synthesized report of key themes, research outcomes and intervention priorities to inform prevention education and future prevention research.
Questions asked in advance of the application deadline will be posted here with their answers. Updated July 6, 2016
Q: The main deliverable is a full report to Prostate Cancer Canada. However, is the project lead and team able to publish their results in the peer reviewed literature?
Q: Should the review focus on RCT evidence or should the review to be more comprehensive (including cohort, case-control and laboratory studies)? The report would then discuss the quality of evidence from these various sources.
A: PCC encourages review of all existing evidence with a discussion of the quality of evidence from the various sources.
6) Please provide the names of two references for each proposed candidate, and project lead, who can speak to the relevant work of the candidate(s) and project lead.
8) Within your proposal please speak to the scope of the project, including how many documents, publications, etc. you anticipate being able to systematically review.
9)Please draft a proposed outline for your final report, which includes brief description of each section of the report.
Q: If we are successful in receiving the grant, the full amount of $25,000 is transferred to us only upon delivery of the final report (after completion of the project)?
A: Yes. Payment will be made by invoice upon delivery of the final report. If the successful proponent requires an alternate payment arrangement, adjustments will be considered on a case by case basis.
Q: Can we address select modifiable risk factors to address in the systematic review or should all modifiable risk factors be included?
A: PCC is requesting that the systematic review be as comprehensive as possible, reviewing all modifiable risk factors for prostate cancer.
A: There are no minimum qualifications required for the project team. The review panel will make recommendations as to which proposal should be funded based on the following criteria:
Q: Would a computer purchase count as equipment (non-allowable) or research materials (allowable)? Similarly, would an EndNote licence count as an allowable expense?
A: Computer purchase would count as equipment (non-allowable), while an EndNote license would be an allowable expense.
In cases of acute bacterial prostatitis, IV infusions of certain antibiotics may be administered to rid the body of infection. Your physician will administer these IV infusions, and hospitalization may be required.
Both Levaquin and Cipro I.V. and other flouroquinolones contain a black box warning such as the following:
Fluoroquinolones are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants.
Fluoroquinolones may exacerbate muscle weakness in persons with myasthenia gravis. Avoid CIPRO/LEVAQUIN in patients with known history of myasthenia gravis.
Levaquin and other antibiotic medications should be administered with caution in patients who have a renal deficiency. In cases of renal problems, physicians should monitor patients carefully and provide laboratory studies prior to treatment.
Levaquin injection should not be put into the same IV line with any solution containing multivalent cations, such as magnesium.
Flexible containers should not be used in series connections. This may result in air embolism as a result of air extraction from the primary container.
Discuss any allergies to medications with your physician before treatment, particularly with regard to hypersensitivity to Cipro, any quinolone antibiotics, or any components of these drugs.
Cipro I.V. and other fluoroquinolones are linked to an elevated risk of tendinitis and tendon rupture. If involving the Achilles tendon, a rupture may require surgery. Tendinitis and rupture in the shoulder, hand, biceps, thumb, as well as other tendons may also occur.
Cipro and other quinolones should be administered cautiously in patients with CNS disorders such as epilepsy.
Severe or fatal reactions have occurred in patients who receive IV Cipro simultaneously with Theophylline.
Antibiotics, including Cipro, are known to cause clostridium difficile associated diarrhea (CDAD) ranging from mild diarrhea to fatal colitis.
If you have acute bacterial prostatitis, your physician may determine an IV infusion is necessary to rid the body of infection.
Levaquin is used intravenously if a physician determines a patient cannot tolerate an oral form of the dose.
The standard Levaquin injection dose is 500 mg every 24 hours for 28 days. It is administered by slow infusion over the course of an hour each time.
Single-use vials of Levaquin should be diluted before use. The diluted solution should be 5 mg/mL prior to use. The following solutions are compatible with Levaquin:
Levaquin injection is also available as a premixed solution in 5% dextrose for single-use. In this case, no further dilution is required.
If using Levaquin injection in premixed flexible containers, your physician should squeeze the inner bag to check for tiny leaks. If leaks are present or if the seal has been previously broken, the solution should be discarded.
Cipro injection concentrate must be diluted before use. This drug must be diluted with a compatible IV solution for a concentration of 1 to 2 mg/mL.
Be sure to maintain sufficient hydration while receiving intravenous Levaquin to prevent urine from becoming highly concentrated.
IV infused drugs should be visually examined before use; your physician should look for particles and discoloration whenever the solution and container allow.
Minimal data is available regarding the compatibility of Levaquin injection and other IV medications; other IV drugs should not be administered simultaneously in the same line. The line should be flushed with a compatible solution prior to and following use with Levaquin injection.
Treatment of Cipro I.V. should be discontinued if a patient experiences tendon pain, swelling, inflammation or rupture.
Before using Cipro, inform your physician if you are allergic to it or other quinolones. Discuss any other allergies you have with your doctor.
Cipro may cause QT prolongation, which rarely causes serious or fatal rapid or abnormal heartbeat, dizziness, or fainting. If this occurs, seek immediate medical attention.
Inform your physician if you experience symptoms of high or low blood sugar during treatment of Cipro. Your physician should monitor your blood sugar levels carefully, especially in diabetic patients.
When taking this medication, exercise caution when driving, operating machinery, or performing other potentially dangerous tasks, as Cipro may cause dizziness. Limit alcohol consumption.
Avoid excessive exposure to the sun, as well as tanning booths. While outdoors, wear protective clothing and use sunscreen.
Diluted Levaquin injection is stable for 72 hours if stored at or below 25°C (77°F). It is stable for 14 days if refrigerated at 5°C (41°F) in plastic containers. Frozen diluted solutions in glass or plastic containers are stable for six months if stored at -20°C (-4°F).
Thaw frozen solutions at room temperature or in a refrigerator. Do not place in warm water or microwave to speed up the thawing process. Do not refreeze a solution if it has been thawed already.
Cipro should be stored in vials between 41° and 86°F. Flexible containers should be stored between 41° and 77°F.
Diluted Cipro injection is stable for up to 14 days in a refrigerator (36° to 46°F) or at room temperature below 86°F.